Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial

2

Sept 22 (Reuters) – Swiss drugmaker Roche said on Tuesday its experimental dual-acting obesity drug helped overweight or obese patients with type 2 diabetes lower blood sugar levels and lose an

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)